Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Doxorubicin Hydrochloride Liposome Injection is indicated for the treatment of Ovarian Cancer, AIDS-Related Kaposi's Sarcoma, and Multiple Myeloma
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Alembic Pharmaceuticals commissions new facility at Pithampur
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Subscribe To Our Newsletter & Stay Updated